{"article_id": "SYK_q4_2020.txt", "article": ["our fourth quarter organic sales declined to roughly 1 % , reflecting the impact of a resurgence of covid - 19 infections offset by a continuation of emergent procedures and strong performance by our large capital products .", "throughout the quarter , we maintained the financial discipline instituted at the beginning of a pandemic which combined with a favorable tax rate , led to an adjusted earnings per share of $ 2.81 in the quarter , up approximately 13 % versus 2019 .", "and we delivered impressive cash flow from operations which exceeded $ 3 billion for the full year .", "this slowdown in elective procedures had a negative impact on our more deferrable businesses , which make up approximately 40 % to 50 % of our total sales .", "during the year , our mako install base grew by 33 % and exceeded another milestone with over 100 robots sold and installed in the fourth quarter .", "in the fourth quarter , approximately 44 % of our total knees will make their knee procedures , a trend that continues to increase .", "the shift toward cementless knees also continued and in the fourth quarter , cementless knees made up 42 % of our u.s. knee procedures .", "the combination of stryker and wright will continue to drive innovation that enhances our customers ' ability to address patient needs across to more than $ 3 billion extremities market .", "our organic sales decline was 1.1 % in the quarter .", "pricing in the quarter was unfavorable 0.8 % from the prior year , while foreign currency had a favorable 1.2 % impact on sales .", "for the quarter , u.s. organic sales declined 1.5 % , reflecting the slowdown in elective procedures as a result of the pandemic , somewhat offset by strong demand for mako , medical products , and neurovascular products .", "organic sales decline for the year was 4.8 % , with a u.s. decline of 5.8 % , and an international decline of 2.1 % .", "2020 had one additional selling day compared to 2019 and for the year , price had an unfavorable 0.7 % impact on sales .", "our adjusted quarterly earnings per share of $ 2.81 increased 12.9 % from the prior year , reflecting strong financial discipline , good operating expense control , and a favorable operational tax rate .", "our fourth quarter earnings per share was positively impacted by $ 0.03 from foreign currency .", "our full - year earnings per share was $ 7.43 , which is a decline of 10 % , reflecting the impact of lower sales , especially in q2 , as well as the impact of idling certain manufacturing facilities during the year , offset by strong expense discipline throughout the year .", "orthopaedics had constant currency sales growth of 2.8 % and an organic sales decline of 5.8 % , including an organic decline of 5.7 % in the u.s .", "this reflects a slowdown in elective procedures related to covid - 19 and a very strong prior - year comparable as q4 2019 u.s. organic growth was 7.2 % .", "other ortho grew 12.3 % in the u.s. , primarily reflecting strong demand for our mako robotic platform , partially offset by declines in bone cement .", "internationally , orthopaedics declined 6 % organically , which also reflects the covid - 19 related to procedural slowdown , especially in europe .", "on a comparable basis for the full year , wright had a 10.3 % decline , mainly driven by the covid - 19 related slowdown in the second quarter .", "in the quarter , medsurg had constant currency growth of 1.5 % and organic growth of 1.3 % , which included 2.2 % growth in the u.s. instruments had u.s. organic sales growth of 4.5 % .", "endoscopy had a u.s. organic sales decline of 7 % primarily impacted by the slowdown in the capital businesses offset by gains in the sports medicine business , which grew over 9 % in the quarter .", "the medical division had u.s. organic growth of 9.7 % reflecting solid performances in patient care , emergency care , and its sage businesses .", "internationally , medsurg had an organic sales decline of 2.4 % , reflecting a general slowdown in instruments and endoscopy businesses and strong comparables across most geographies .", "neurotechnology and spine had constant currency and organic growth of 2.1 % .", "our u.s. neurotech business posted an organic decline of 1.2 % as procedural deferrals impacted sales in the quarter .", "internationally , neurotechnology and spine had organic growth of 13.5 % .", "our adjusted gross margin of 65.1 % was unfavorable approximately 120 basis points from the prior - year quarter .", "adjusted r&d spending was 5.5 % of sales .", "our adjusted sg&a was 30.3 % of sales , which was favorable to the prior - year quarter by 200 basis points .", "in summary for the quarter , our adjusted operating margin was 29.2 % of sales , which is a 90 basis points improvement over the prior - year quarter and reflects the impact of the spending discipline previously discussed .", "our fourth quarter had an adjusted effective tax rate of 8 % .", "our full - year effective tax rate was 12.6 % .", "and we expect our full - year effective tax rate to be in the range of 15.5 % to 16.5 % .", "focusing on the balance sheet , we ended the year with $ 3 billion of cash and marketable securities , and total debt of $ 14 billion .", "during the quarter , we executed the wright medical acquisition , which resulted in the disbursement of $ 5.6 billion , inclusive of the retirement of wright 's convertible debt .", "turning to cash flow , our year - to - date cash from operations was approximately $ 3.3 billion .", "we will not be repurchasing any shares and we anticipate that capital expenditures will be approximately $ 650 million .", "anticipating a more normalized year in 2021 and a ramping of investment in our businesses , we expect the free cash flow conversion rate as a percent of adjusted net earnings , including the one -- excluding the one - time impacts from the wright medical integration , about 70 % to 80 % .", "given this variability , we expect organic sales growth to be in the range of 8 % to 10 % for the full year 2021 when compared to 2019 .", "consistent with the pricing environment experienced in both 2019 and 2020 , we would expect continued unfavorable price reductions of approximately 1 % .", "however , excluding the dilutive impact from wright , we do anticipate expansion of 30 to 50 basis points of operating margin in 2021 for our legacy stryker business compared to 2019 .", "finally , for 2021 , we expect adjusted net earnings per diluted share to be in the range of $ 8.80 to $ 9.20 for the full year .", "this includes the previously announced $ 0.10 dilution , driven by the addition of the wright medical business for the full year .", "we also reiterate our previous guidance on cost - saving synergies from the deal of approximately $ 100 million to $ 125 million over the next three years ."], "summary_gold": "q4 adjusted earnings per share $ 2.81 .<q>quarterly organic net sales decreased 1.1 % .<q>compname says expect 2021 organic net sales growth to be in range of 8 % to 10 % from 2019 .<q>sees q1 2021 adjusted earnings per share $ 8.80 to $ 9.20 .<q>sees 2021 adjusted earnings per share $ 8.80 to $ 9.20 .", "summary_pred": "our fourth quarter had an adjusted effective tax rate of 8 % .<q>in summary for the quarter , our adjusted operating margin was 29.2 % of sales , which is a 90 basis points improvement over the prior - year quarter and reflects the impact of the spending discipline previously discussed .<q>internationally , orthopaedics declined 6 % organically , which also reflects the covid - 19 related to procedural slowdown , especially in europe .<q>consistent with the pricing environment experienced in both 2019 and 2020 , we would expect continued unfavorable price reductions of approximately 1 % .<q>other ortho grew 12.3 % in the u.s. , primarily reflecting strong demand for our mako robotic platform , partially offset by declines in bone cement .<q>however , excluding the dilutive impact from wright , we do anticipate expansion of 30 to 50 basis points of operating margin in 2021 for our legacy stryker business compared to 2019 .<q>anticipating a more normalized year in 2021 and a ramping of investment in our businesses , we expect the free cash flow conversion rate as a percent of adjusted net earnings , including the one -- excluding the one - time impacts from the wright medical integration , about 70 % to 80 % .<q>focusing on the balance sheet , we ended the year with $ 3 billion of cash and marketable securities , and total debt of $ 14 billion .<q>internationally , neurotechnology and spine had organic growth of 13.5 % .<q>we will not be repurchasing any shares and we anticipate that capital expenditures will be approximately $ 650 million .<q>we also reiterate our previous guidance on cost - saving synergies from the deal of approximately $ 100 million to $ 125 million over the next three years .<q>turning to cash flow , our year - to - date cash from operations was approximately $ 3.3 billion .<q>during the year , our mako install base grew by 33 % and exceeded another milestone with over 100 robots sold and installed in the fourth quarter .<q>this slowdown in elective procedures had a negative impact on our more deferrable businesses , which make up approximately 40 % to 50 % of our total sales .<q>our adjusted quarterly earnings per share of $ 2.81 increased 12.9 % from the prior year , reflecting strong financial discipline , good operating expense control , and a favorable operational tax rate .<q>internationally , medsurg had an organic sales decline of 2.4 % , reflecting a general slowdown in instruments and endoscopy businesses and strong comparables across most geographies .", "len_article": 46, "len_summary_gold": 5, "len_summary_pred": 16, "len_sent_scores": 46}